Business Context and Reporting Period
This Form 8-K was filed by Aileron Therapeutics, Inc. (trading symbol: ALRN) on December 7, 2021, reporting an event that occurred on December 6, 2021. The company is incorporated in Delaware and its common stock is listed on the Nasdaq Capital Market.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on a listing deficiency related to the company's stock price.
Material Changes
On December 6, 2021, the company received a deficiency letter from the Nasdaq Listing Qualifications Department. The letter notified the company that its common stock bid price had closed below the minimum $1.00 per share requirement for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2).
Outlook, Risks, and Management Commentary
- Compliance Period: The company has been granted an initial 180-day compliance period, ending June 6, 2022, to regain compliance.
- Regaining Compliance: To cure the deficiency, the stock must close at $1.00 or more per share for 10 consecutive business days before the compliance deadline.
- Second Compliance Period: If the company fails to regain compliance by June 6, 2022, it may be eligible for an additional 180-day period if it meets other listing standards and notifies Nasdaq of its intent to cure, potentially via a reverse stock split.
- Delisting Risk: If the company fails to regain compliance and is ineligible for or fails the second compliance period, Nasdaq will issue a delisting notice. The company may appeal this determination, but success is not assured.
- Management Action: Management intends to monitor the stock price and may consider a reverse stock split to regain compliance, though there is no assurance of success.
Investor Verification Checklist
- Verify the current closing bid price of ALRN stock to assess proximity to the $1.00 threshold.
- Monitor the company's stock price for 10 consecutive days to determine if the initial compliance period can be satisfied.
- Review future filings for announcements regarding a potential reverse stock split.
- Check for any updates on the company's eligibility for the second 180-day compliance period if the initial deadline is missed.